Nanobiotix SA reported cash and cash equivalents of €20.4 million as of September 30, 2025. The company closed a royalty financing transaction with HealthCare Royalty, triggering a $50 million upfront payment, with an additional $21 million expected one year post-closing upon reaching certain conditions. This financing is expected to extend cash visibility into early 2028. Key business developments included the transfer of the NANORAY-312 Phase 3 head and neck cancer study sponsorship to Johnson & Johnson in the majority of regions, progress in the JNJ-1900 (NBTXR3) program with first data from a Phase 1 esophageal cancer study, and advancement of the Curadigm Nanoprimer program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591630-en) on November 24, 2025, and is solely responsible for the information contained therein.